The U.S. Food and Drug Administration expanded the indication of Supernus Pharmaceuticals Inc.’s Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.
https://www.pharmalive.com/wp-content/uploads/2022/05/FDA-Approves-New-Nonstimulant-Option-for-Adults-with-ADHD-BioSpace-5-2-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-05-02 11:42:382022-05-02 15:48:15FDA Approves New Nonstimulant Option for Adults with ADHD